European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2024, Volume and Issue: 51(11), P. 3373 - 3385
Published: May 16, 2024
Language: Английский
Diagnostics, Journal Year: 2023, Volume and Issue: 13(12), P. 2018 - 2018
Published: June 9, 2023
Despite revolutionizing the field of oncological imaging, Positron Emission Tomography (PET) with [
Language: Английский
Citations
53
Diagnostics, Journal Year: 2025, Volume and Issue: 15(2), P. 218 - 218
Published: Jan. 19, 2025
Background/Objectives: Over the past four years, 68Ga-fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) has been established at a tertiary cancer care facility in Jordan. This retrospective study aims to explore tracer uptake metrics across various epithelial neoplasms, identify diagnostic pitfalls associated with 68Ga-FAPI PET/CT, and evaluate influence of PET/CT staging results on changes therapeutic intent compared gold standard molecular imaging modalities. Methods: A total 48 patients biopsy-confirmed solid tumors underwent 77 examinations for assessment, encompassing neoplasms originating from gastrointestinal tract, head neck, hepatobiliary system, pancreas, breast, lung. Results: Notably, pancreaticobiliary exhibited highest uptake, mean maximum standardized values (SUVmax) tumor-to-background ratios (TBR) surpassing 10. comparative sub-analysis PET 20 treatment-naïve revealed significant correlation between tumor grade (Spearman’s rho 0.83; p = 0.00001). Importantly, influenced treatment decisions 35.5% cases, primarily resulting an escalation management plans. 220 challenges were identified 88.3% scans, predominantly within musculoskeletal attributed degenerative (99 observations). Conclusions: comprehensive analysis highlights potential significance oncological strategy, while also emphasizing necessity meticulous interpretation mitigate challenges.
Language: Английский
Citations
2
Biosensors, Journal Year: 2024, Volume and Issue: 14(2), P. 100 - 100
Published: Feb. 16, 2024
Cancers of unknown primary (CUP) exhibit significant cellular heterogeneity and malignancy, which poses challenges for diagnosis treatment. Recent years have seen deeper insights into the imaging, pathology, genetic characteristics CUP, driven by interdisciplinary collaboration evolution diagnostic therapeutic strategies. However, due to their insidious onset, lack evidence-based medicine, limited clinical understanding, diagnosing treating CUP remain a challenge. To inspire more creative fantastic research, herein, we report highlight recent advances in strategies CUP. Specifically, discuss advanced technologies, including 12-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) or 68Ga-FAPI (fibroblast activation protein inhibitor) PET/CT, liquid biopsy, molecular diagnostics, self-assembling nanotechnology, artificial intelligence (AI). In particular, discussion will extend effective treatment techniques currently available, such as targeted therapies, immunotherapies, bio-nanotechnology-based therapeutics. Finally, novel perspective on directions future is discussed.
Language: Английский
Citations
11
npj Imaging, Journal Year: 2024, Volume and Issue: 2(1)
Published: Nov. 13, 2024
Abstract The discovery of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET) has paved the way for a new class PET tracers that target tumor microenvironment (TME) rather than itself. Although 18 F-fluorodeoxyglucose (FDG) is most common tracer used in clinical imaging cancer, multiple studies have now shown family FAP ligands commonly outperform FDG detecting cancers, especially those known to lower uptake on FDG-PET. Moreover, FAPI-PET will applications benign fibrotic or inflammatory conditions. Thus, even while are development and yet enter guidelines, significant body literature emerged FAPI-PET, suggesting it important roles. This article summarizes current state as well potential uses theranostic agent.
Language: Английский
Citations
10
Abdominal Radiology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 3, 2025
Language: Английский
Citations
1
European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2023, Volume and Issue: 51(3), P. 852 - 861
Published: Oct. 7, 2023
Language: Английский
Citations
15
Annals of Nuclear Medicine, Journal Year: 2023, Volume and Issue: 37(11), P. 583 - 595
Published: Sept. 25, 2023
Language: Английский
Citations
14
BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)
Published: June 7, 2024
Abstract Background [ 18 F]Fluorodeoxyglucose ([ F]FDG) positron emission tomography (PET) is recommended during diagnostic work-up for ovarian cancer; however, F]FDG PET has several inherent limitations. The novel oncologic PET-tracer fibroblast activation protein inhibitor (FAPI) demonstrated promising results in multiple cancer types, including cancer, and could overcome the limitations of PET; high-quality clinical studies are lacking. primary objective present study to compare accuracy 68 Ga]Ga-FAPI-46 PET/CT patients investigate how this potential difference impacts staging patient management. Methods design Fifty consecutive will be recruited from Aalborg University Hospital, Denmark. This a single-center, prospective, exploratory trial that adheres standards reporting (STARD). conducted under continuous Good Clinical Practice monitoring. eligibility criteria as follows: (1) biopsy verified newly diagnosed or high risk referred with PET/CT; (2) resectable disease, i.e., candidate debulking surgery neoadjuvant chemotherapy followed by interval surgery. All subjects undergo at staging, before (Group A + B), addition conventional imaging (including PET/CT). Study Group B an additional following prior study-related PET/CTs blinded, treatment allocation based on common practice accordance current guidelines. histopathology surgical specimens serve reference standard. recruitment period 2 years estimated; currently recruiting. Discussion To our knowledge, represents largest, most extensive, meticulous prospective FAPI thus far. aims obtain reliable estimation PET/CT, shed light importance examine applicability evaluating response. Trial registration clinicaltrials.gov: NCT05903807, 2nd June 2023; euclinicaltrials.eu EU CT Number: 2023-505938-98-00, authorized 11th September 2023.
Language: Английский
Citations
6
Radiation Oncology, Journal Year: 2024, Volume and Issue: 19(1)
Published: April 4, 2024
Abstract Background Fibroblast activation protein (FAP) is expressed in the tumor microenvironment (TME) of various cancers. In our analysis, we describe impact dual-tracer imaging with Gallium-68-radiolabeled inhibitors FAP (FAPI-46-PET/CT) and fluorodeoxy-D-glucose (FDG-PET/CT) on radiotherapeutic management primary esophageal cancer (EC). Methods 32 patients EC, who are scheduled for chemoradiation, received FDG FAPI-46 PET/CT same day (dual-tracer protocol, 71%) or two separate days (29%) We compared functional volumes (FTVs), gross (GTVs) stages before after PET-imaging. Changes treatment were categorized as “minor” (adaption radiation field) “major” (change regimen). Immunohistochemistry (IHC) staining was performed all available tissue. Results Primary detected FAPI-46/dual-tracer scans 30/32 (93%) scans. Compared to initial staging CT scan, 12/32 (38%) upstaged nodal status combination PET Two lymph node metastases only visible FAPI-46/dual-tracer. New distant metastasis observed 2/32 (6%) following FAPI-4 -PET/CT. Our findings led larger RT fields (“minor change”) 5/32 (16%) changed regimen (“major 3/32 PET/CT. GTVs FDG-PET/CT (mean 99.0 vs. 80.3 ml, respectively ( p < 0.001)) similar results nuclear medical FTVs. IHC revealed heterogenous FAP-expression specimens H-score: 36.3 (SD 24.6)) without correlation between expression FAPI tracer uptake Conclusion report first data use receive RT. Tumor high not depending TME. Further, had relevant this setting. calls prospective evaluation improve clinical outcomes EC.
Language: Английский
Citations
5
Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(6), P. 716 - 716
Published: May 31, 2024
The role of fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) is emerging for the assessment non-oncological diseases, such as inflammatory and infectious even if evidence in literature still its initial phases. We conducted a systematic search Scopus, PubMed/MEDLINE, Embase, Cochrane library databases studies published before 31 December 2023 reporting disease imaging with FAPI PET/CT. included twenty-one total 1046 patients. most frequent studied was lung interstitial disease, investigated six 200 patients, followed by bone joint diseases two 185 IgG4-related 53 Crohn’s 30 Despite heterogeneity terms study design technical features, PET/CT showed high detection rate diagnostic role. Moreover, when compared 2-[18F]FDG (n = 7 studies), seems to have better performances. presence chronic inflammation tissue remodeling, typical immune-mediated conditions, may be underlying mechanism uptake.
Language: Английский
Citations
5